Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — Ziopharm Oncology — 37th Annual J.P. Morgan Healthcare Conference 2019
21 slides from Alaunos Therapeutics's conference presentation, Jan 10, 2019
Slide 1: 37th Annual J.P. Morgan Healthcare Conference January 2019
Ziopharm ONCOLOGY 37th Annual J.P. Morgan Healthcare Conference January 2019 Exhibit 99.1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains certain forward-looking information about Ziopharm Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking stat
Slide 3: Transformed Ziopharm
Transformed Ziopharm To solve the current commercial limitations of cost and scalability of approved CAR-T To harness the power of IL-12 as a drug to address difficult-to-treat solid tumors with precision To deliver end-to-end and scalable TCR-T cell therapy to treat solid tumors
Slide 4: Ziopharm: Summary and Vision
Ziopharm: Summary and Vision 2019 and beyond Executional excellence All programs in clinic in 2019 5 clinical trials In-house capabilities: Expanding laboratory and manufacturing in Houston 4Q2018 Accomplishments Redefined license agreement with Intrexon and Precigen in October 2018 Eliminated $157M
Slide 5: Strong Partnerships in Place
Strong Partnerships in Place Infusing TCR-T cells targeting solid tumor neoantigens with Sleeping Beauty technology & Steven Rosenberg Advancing Controlled IL-12 in combination with Libtayo for recurrent GBM Deploying Sleeping Beauty CD19-specific CAR-T for very rapid manufacturing Expanding Sleepin
Slide 6: Sleeping Beauty TCR-T Program
Sleeping Beauty TCR-T Program
Slide 7: T cells modified to express neoantigen-specific TCRs for metastatic solid tumors
T cells genetically modified to express neoantigen-specific TCRs represent the best opportunity for targeting metastatic solid tumors The best TCRs are unique for each patient T cells with multiple specificities (multiple TCRs) are required to prevent relapse
Slide 8: Sleeping Beauty Scalability Solves the manufacturing challenge of targeting neoantigens
Sleeping Beauty Scalability Solves the manufacturing challenge of targeting neoantigens Non-viral solution is scalable: To express multiple unique TCRs to target multiple neoantigens To produce Multiple TCRs meet demands of tumor target diversity within one patient To reduce costs and avoid virus wi
Slide 9: Collaborating with NCI on End-to-end Solution to Target Solid Tumors
Ziopharm Collaborating with NCI on End-to-end Solution to Target Solid Tumors Selection of neoantigens 1 2 Selection of TCRs Selection of neoantigens 1 Manufacture T cells 3 2 Selection of TCRs Viral approach to manufacturing TCR-T Sleeping Beauty approach to manufacturing TCR-T
Slide 10: Sleeping Beauty CD19-specific CAR-T Program
Sleeping Beauty CD19-specific CAR-T Program
Slide 11: Viable business model remains elusive
Viable business model remains elusive High cost and reimbursement dynamic is likely unsustainable Centralized manufacturing adds logistical complexities Significant time required to deliver to patients Local, very rapid, simplified, scalable manufacturing Bioengineering resting T cells with CAR and
Slide 12: Strategy for Very-Rapid Manufacturing of CAR-T
Strategy for Very-Rapid Manufacturing of CAR-T Ö Demonstrated Sleeping Beauty with CD19-specific CAR-T Ö Value to Ziopharm CD19: Fully-funded with Eden BioCell CD19: Fully-funded at MD Anderson Undisclosed: Additional validated target Ö Not pursuing new CAR targets Significant progress made on cell
Slide 13: Eden BioCell to take CAR-T CD19 to Asian Markets
Sleeping Beauty third-generation for very rapid manufacturing of CD19-specific CAR-T cell therapy licensed to Eden BioCell for Greater China Eden BioCell funded with up to $35 million entirely from TriArm Therapeutics Ziopharm and TriArm each have 50 percent ownership “Cancer Statistics in China, 20
Slide 14: Controlled IL-12 Platform
Controlled IL-12 Platform
Slide 15: Recurrent Glioblastoma is not Curable; A New Rational Approach is Needed
Recurrent Glioblastoma is not Curable; A New Rational Approach is Needed TARGETS ARE UNKNOWN Current therapies don’t work LOW SURVIVAL RATE Historical overall survival is 5 to 8 months THE SOLUTION: IL-12 as a DRUG Most powerful immuno-stimulant to recruit T cells IMMUNOTHERAPY BEST APPROACH Immune
Slide 16: IL-12 Delivered into Recurrent Glioblastoma can be Controlled
hIL-12 Veledimex** Low-dose steroids*** IL-12 Delivered into Recurrent Glioblastoma can be Controlled by Ziopharm to Improve Survival £: Based on patients and a subset of receiving less than 20mg dexamethasone following surgery, SNO2018 presentation entitled, “A Phase 1 study of Ad-RTS-hIL-12 + vele
Slide 17: IL-12 Monotherapy with Low-dose Steroids Expanded Trial
IL-12 Monotherapy with Low-dose Steroids Expanded Trial Phase 1: Ad-RTS-hIL-12 plus 20mg of veledimex Expansion cohort of monotherapy and guidance for low dose (<20 mg) dexamethasone Enrollment (n=25) completed this week 65% of enrolled patients received low-dose steroids
Slide 18: Controlled IL-12 in Combination with PD-1 Inhibitors for recurrent GBM
Next Logical Step: Controlled IL-12 in Combination with PD-1 Inhibitors for recurrent GBM Phase 2 trial of Controlled IL-12 in combination with PD-1 antibody Libtayo® (cemiplimab-rwlc) to treat patients with rGBM Enroll up to ~30 patients; primary endpoints are safety and efficacy Initiate 1H2019 Ne
Slide 19: Summary of 2019 Milestones: Two Platforms Solving Critical Problems
Summary of 2019 Milestones: Two Platforms Solving Critical Problems Phase 1 Fully enrolled Controlled IL-12 monotherapy expansion cohort 1Q2019 Phase 1 Fully enrolled Controlled IL-12 in combination with OPDIVO 2Q2019 Phase 2 Initiation Controlled IL-12 in combination with Libtayo 1H2019 Phase 1 Fir
Slide 20: All Programs in the Clinic in 2019
All Programs in the Clinic in 2019 Delivers multiple TCRs targeting multiple patient-specific neoantigens End-to-end Sleeping Beauty TCR-T process is clinically advanced NCI/Rosenberg partnership advancing into the clinic Sleeping Beauty platform FDA-cleared for use in clinical trials Most clinicall
Slide 21: Thank you
health si, & Thank you
Ziopharm Oncology — 37th Annual J.P. Morgan Healthcare Conference 2019 on 6ix